Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators.

N Engl J Med. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898.

2.

Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.

van Cruijsen H, Hoekman K, Stam AG, van den Eertwegh AJ, Kuenen BC, Scheper RJ, Giaccone G, de Gruijl TD.

Clin Dev Immunol. 2007;2007:17315. doi: 10.1155/2007/17315.

3.

[Myocardial ischaemia as a result of treatment with capecitabine].

van der Vliet HJ, Kuenen BC.

Ned Tijdschr Geneeskd. 2007 Sep 8;151(36):2016; author reply 2016. Dutch. No abstract available.

PMID:
17953177
4.

A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.

Bröker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, Parker S, Kayitalire L, Lorusso PM, Schellens JH, Giaccone G.

Clin Cancer Res. 2007 Jul 1;13(13):3906-12.

5.

A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.

Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H, Giaccone G.

Clin Cancer Res. 2007 Jun 15;13(12):3642-51.

6.

Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.

Bröker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, Woo MH, Voi M, Gietema JA, de Vries EG, Giaccone G.

Clin Cancer Res. 2006 Mar 15;12(6):1760-7.

7.

Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.

Kuenen BC, Giaccone G, Ruijter R, Kok A, Schalkwijk C, Hoekman K, Pinedo HM.

Clin Cancer Res. 2005 Sep 1;11(17):6240-6.

8.

A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour.

Hansma AH, van Hensbergen Y, Kuenen BC, van Diest PJ, Hanemaaijer R, Meijer S, Pinedo HM, Hoekman K.

J Clin Pathol. 2004 May;57(5):536-8.

9.

[New oncological treatment principle with imatinib].

Kuenen BC, Pinedo HM.

Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2044-5. Dutch.

PMID:
14606348
10.

Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors.

Kuenen BC.

Pathophysiol Haemost Thromb. 2003;33 Suppl 1:13-4. No abstract available.

PMID:
12954992
11.

Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.

Kuenen BC, Levi M, Meijers JC, van Hinsbergh VW, Berkhof J, Kakkar AK, Hoekman K, Pinedo HM.

J Clin Oncol. 2003 Jun 1;21(11):2192-8.

PMID:
12775746
12.

Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K, Harris AL.

Clin Cancer Res. 2003 May;9(5):1648-55.

13.

Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.

Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K.

Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1500-5.

14.

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.

Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G.

J Clin Oncol. 2002 Mar 15;20(6):1657-67.

PMID:
11896117
15.

Effect of providing cancer patients with the audiotaped initial consultation on satisfaction, recall, and quality of life: a randomized, double-blind study.

Ong LM, Visser MR, Lammes FB, van Der Velden J, Kuenen BC, de Haes JC.

J Clin Oncol. 2000 Aug;18(16):3052-60.

PMID:
10944140
16.

Mondor's disease as first thrombotic event in hereditary protein C deficiency and anticardiolipin antibodies.

Wester JP, Kuenen BC, Meuwissen OJ, de Maat CE.

Neth J Med. 1997 Feb;50(2):85-7.

PMID:
9050336
17.

Intravenous leiomyomatosis complicated by Budd-Chiari syndrome.

Kuenen BC, Slee PH, Seldenrijk CA, Wagenaar SS.

Postgrad Med J. 1996 Nov;72(853):686-8. No abstract available.

18.

Non-islet-cell tumour induced hypoglycaemia: a case report and review of literature.

Kuenen BC, van Doorn J, Slee PH.

Neth J Med. 1996 May;48(5):175-9. Review.

PMID:
8710034

Supplemental Content

Loading ...
Support Center